Handelsavisen
prelaunch
PH
PHR.WA Warsaw Stock Exchange Personal Products

Pharmena SA

$3,14
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
26,23 %
Op margin
13,1 %
ROE
-195,6 %
Net margin
-4 192,7 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
$8,78
Open
$8,75
Next earnings
2026-08-28
Ex-dividend
TR 1Y
About

Pharmena SA operates in the Personal Products industry, focusing on the development, production, and distribution of personal care and household products.

Business. Pharmena SA (PHR.WA) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorPersonal & Household Products & Services
IndustryPersonal Products
Generated · model-assisted
Sell-side consensus
BUY20 analysts
14 buy6 hold0 sell
Avg 12m price target15,12

Analyst recommendations

20 analysts · consensus Buy
Buy14
Hold6
Sell0
12-month price target
15,12
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ2 2026 earnings (expected)2026-08-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
20 analysts · indicative
Ownership
not yet wired
Profitability
-195,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PHR.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PHR.WA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ2 2026 earnings (expected)2026-08-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR
    • Congressional trades
    • CongressJosh Gottheimer — Phreesia, Inc. Common Stock2026-03-05 · Democrat · NJ · Sale · $1,001 - $15,000
    • CongressJosh Gottheimer — Phreesia, Inc.2023-10-16 · Democrat · NJ · Purchase · $1,001 - $15,000
    • CongressJosh Gottheimer — Phreesia, Inc.2023-09-15 · Democrat · NJ · Sale · $1,001 - $15,000
    • CongressJosh Gottheimer — Phreesia, Inc.2021-12-15 · Democrat · NJ · Purchase · $1,001 - $15,000
    • CongressJosh Gottheimer — Phreesia, Inc.2020-12-21 · Democrat · NJ · Sale · $1,001 - $15,000

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Pharmena SA (PHR.WA) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorPersonal & Household Products & Services
    IndustryPersonal Products
    AI synthesis
    GENERATED

    Pharmena SA exhibits a strong liquidity position, with a current ratio of 13.97 and cash and equivalents amounting to 22,176,000 PLN, which significantly exceeds its total liabilities of 1,797,000 PLN. The company's debt-to-equity ratio is 0.01, indicating a conservative capital structure with minimal reliance on debt financing. Despite this, the company reported a negative net income of -45,281,000 PLN, which is a significant deviation from typical performance in the Personal Products industry.

    The company's profitability metrics are notably weak, with a return on equity of -1.9557 and a return on assets of -1.8149, both of which are far below the industry median for the Personal Products sector. This suggests that Pharmena is underperforming in terms of generating returns for shareholders and utilizing its assets efficiently. Gross profit of 852,000 PLN and operating income of 142,000 PLN are insufficient to offset the company's net loss, indicating potential operational inefficiencies or cost overruns.

    Pharmena's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests that the company may have a relatively undiversified business model. This could expose the company to higher risks if demand for its products declines in a specific market or customer base. The lack of detailed segment reporting also limits the ability to assess the performance of individual product lines or geographic regions.

    Looking ahead, the company's growth trajectory is uncertain, as the available data does not provide forward-looking revenue projections or outlooks for the current or next fiscal year. The negative net income and weak profitability metrics suggest that the company may face challenges in sustaining growth without significant operational improvements or cost reductions. The absence of a clear growth strategy or capital allocation plan further complicates the assessment of future performance.

    Risk factors for Pharmena include the potential for dilution, although the risk is currently assessed as low. The company has not issued additional shares recently, and there are no immediate filing-based liquidity or dilution flags. However, the negative net income and weak returns could pressure the company to raise capital in the future, which may involve issuing new shares and diluting existing shareholders. The company's liquidity position is strong, but the negative free cash flow of -46,418,000 PLN indicates that the company is not generating sufficient cash to fund operations and growth.

    Recent events and filings do not provide specific details on strategic initiatives or operational changes, but the company's financial performance suggests that it may be undergoing a period of restructuring or cost optimization. The absence of recent transcripts or detailed disclosures limits the ability to assess the company's strategic direction and management's response to current challenges. Investors should monitor future filings and earnings reports for more insight into the company's financial health and strategic plans.

    Key takeaways
    • Pharmena SA has a strong liquidity position with a current ratio of 13.97 and significant cash reserves.
    • The company is underperforming in terms of profitability, with a negative return on equity and return on assets.
    • The lack of segment and geographic revenue breakdowns suggests a potentially undiversified business model.
    • The company's growth trajectory is uncertain, with no clear forward-looking revenue projections.
    • The risk of dilution is currently low, but the negative net income and weak returns could pressure the company to raise capital in the future.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Analysts project 381.5% upside to a mean price target of 15.12 PLN, signaling strong market confidence in future performance.

    Debt-to-equity ratio of 0.01 is significantly lower than the cohort median of 0.14, reflecting a conservative capital structure.

    Net income improved by 19.6% year-over-year, demonstrating a positive trajectory in profitability despite recent revenue declines.

    Low dilution, liquidity, and credit risk flags suggest a stable financial environment with minimal immediate structural threats.

    BEAR CASE · 3

    Net margin of -41.9% places the company in the bottom quartile of its cohort, signaling poor profitability relative to peers.

    Return on equity of -1.96% ranks in the bottom quartile, indicating inefficient use of shareholder capital compared to competitors.

    Cash conversion ratio of -0.68 is in the bottom quartile, suggesting significant challenges in converting earnings into cash.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2019-11-14
    Q3 2019 · Quarter highlights

    Revenue PLN 386.0k, +160,8% YoY; Operating income −29,2% YoY.

    RevenuePLN 386.0k+160,8 % YoY
    Operating income-PLN 876.0k−29,2 % YoY
    Net income-PLN 700.0k−15,9 % YoY
    Free cash flow-PLN 751.0k−19,6 % YoY
    EPS
    Operating cash flow-PLN 1.8M+24,4 % YoY
    Financials
    Income statement
    RevenuePLN 386.0k
    Gross profitPLN 356.0k
    Operating income-PLN 876.0k
    Net income-PLN 700.0k
    Margins
    Gross margin92.2%
    Operating margin-226.9%
    Net margin-181.3%
    FCF margin-194.6%
    Balance sheet
    Total assetsPLN 12.2M
    Total liabilitiesPLN 945.0k
    Total equityPLN 11.2M
    Cash & equivalentsPLN 1.0k
    Long-term debtPLN 202.0k
    Cash flow
    Operating cash flow-PLN 1.8M
    CapEx-PLN 130.0k
    Free cash flow-PLN 751.0k
    SBC
    P&L flow · revenue → net income
    Revenue PLN 386.0kOperating costs PLN 1.3MNet income PLN 700.0k
    Highlights
    • Revenue PLN 386.0k, +160,8% YoY
    • Operating income −29,2% YoY
    • Net income −15,9% YoY
    • Free cash flow −19,6% YoY
    • Net margin -181.3%

    Valuation TTM

    Market price
    $3,14
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $23.2M
    Net cash
    $22.0M
    Current ratio
    14.0
    Debt / equity
    0.0
    ROA
    -1.8%
    ROE
    -2.0%
    Cash conversion
    -68.0%
    CapEx / revenue
    -1.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships4 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries4
    EX21:16a375b7e11dEX21:16a375b7e11dSubsidiarie97%
    EX21:481681ab9c44EX21:481681ab9c44Subsidiarie97%
    EX21:a970058355feEX21:a970058355feSubsidiarie97%
    EX21:f1b4d465852dEX21:f1b4d465852dSubsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$9,00
    Mean$15,12
    Median$14,00
    High$23,00
    Spot$3,14
    +381.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin13,2 %Above P75
    Net Margin-4 192,7 %Bottom quartile
    ROE-195,6 %Bottom quartile
    Capex / Rev-120,5 %Bottom quartile
    D/E0,01Above P75
    Cash Conv-0,68Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Pharmena SA Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    Net buying3 buys · 10 sellsnet $10,1M15 insiders · last 365d
    • Munson GillianDirector · Common StockOther 685 @ $10,73$7K · 2026-07-31
    • Goldstein LainieDirector · Common StockOther 377 @ $10,73$4K · 2026-07-31
    • Hui YvonnePrincipal Accounting Officer · Common StockSold 1 247 @ $10,92$14K · 2026-07-16
    • Linetsky DavidPresident, Network Solutions · Common StockOther 69 @ $10,76$742 · 2026-07-15
    • Hui YvonnePrincipal Accounting Officer · Common StockOther 937 @ $10,76$10K · 2026-07-15
    • Egbuonu-Davis LisaDirector · Common StockSold 536 @ $10,70$6K · 2026-07-14
    • Hui YvonnePrincipal Accounting Officer · Common StockSold 1 371 @ $10,84$15K · 2026-07-06
    • Hui YvonnePrincipal Accounting Officer · Common StockOther 1 371 @ $8,75$12K · 2026-06-30
    • Hoffman Allison CGeneral Counsel & Secretary · Common StockOther 1 265 @ $8,75$11K · 2026-06-30
    • Egbuonu-Davis LisaDirector · Common StockSold 2 546 @ $9,53$24K · 2026-06-25
    • Egbuonu-Davis LisaDirector · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
    • Kessler JonDirector · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
    • Sayar RaminDirector · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
    • Munson GillianDirector · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
    • Smith Mark DouglasDirector · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
    • Goldstein LainieDirector · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
    • Hui YvonnePrincipal Accounting Officer · Common StockOther 325 @ $8,77$3K · 2026-05-18
    • Hui YvonnePrincipal Accounting Officer · Common StockSold 431 @ $8,85$4K · 2026-05-18
    • CAHILL EDWARD LDirector · Common StockOther 1 085 @ $9,21$10K · 2026-04-30
    • Goldstein LainieDirector · Common StockOther 1 085 @ $9,21$10K · 2026-04-30
    • Munson GillianDirector · Common StockOther 1 085 @ $9,21$10K · 2026-04-30
    • Hoffman Allison CGeneral Counsel & Secretary · Common StockSold 6 176 @ $9,06$56K · 2026-04-20
    • Hui YvonnePrincipal Accounting Officer · Common StockSold 1 327 @ $9,28$12K · 2026-04-17
    • Linetsky DavidPresident, Network Solutions · Common StockOther 229 @ $9,17$2K · 2026-04-16
    • Hui YvonnePrincipal Accounting Officer · Common StockSold 10 063 @ $9,08$91K · 2026-04-16

    Short positioning

    3.5Mshares short+1.4% vs prior
    4.41days to cover
    53.1%short of daily vol
    25.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PHR.WACanonical
    Warsaw Stock Exchange · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    PHREX21:16aEX21:481EX21:a97EX21:f1bPersonal Produ
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2026-01-31 vs 2025-01-31): 164.2%Derived (calculated)
    • Cash & equivalents (YoY) (2026-01-31 vs 2025-01-31): -12.3%Derived (calculated)
    • EPS (diluted) (YoY) (2026-01-31 vs 2025-01-31): 103.9%Derived (calculated)
    • EPS (basic) (YoY) (2026-01-31 vs 2025-01-31): 103.9%Derived (calculated)
    • Total assets (YoY) (2026-01-31 vs 2025-01-31): 70.9%Derived (calculated)
    • Shareholders' equity (YoY) (2026-01-31 vs 2025-01-31): 27.3%Derived (calculated)
    • Revenue (YoY) (2026-01-31 vs 2025-01-31): 14.5%Derived (calculated)
    • R&D expense (YoY) (2026-01-31 vs 2025-01-31): 3.5%Derived (calculated)
    • Operating income (YoY) (2026-01-31 vs 2025-01-31): 88.6%Derived (calculated)
    • Operating cash flow (YoY) (2026-01-31 vs 2025-01-31): 143.4%Derived (calculated)
    • Net margin (FY 2026-01-31): 0.5%Derived (calculated)
    • Return on equity (FY 2026-01-31): 0.7%Derived (calculated)
    • Return on assets (FY 2026-01-31): 0.3%Derived (calculated)
    • Current ratio (FY 2026-01-31): 1.53xDerived (calculated)
    • Debt-to-equity (FY 2026-01-31): 0.97xDerived (calculated)
    • Net income (YoY) (2026-01-31 vs 2025-01-31): 103.9%Derived (calculated)
    • Capex (YoY) (2026-01-31 vs 2025-01-31): 27.5%Derived (calculated)
    • Long-term debt (YoY) (2026-01-31 vs 2025-01-31): 37.2%Derived (calculated)
    • Revenue (annual): USD 480.59MSEC XBRL filing
    • Current assets (annual): USD 279.84MSEC XBRL filing
    • Pre-tax income (annual): USD -8.94MSEC XBRL filing
    • Long-term debt (annual): USD 2.66MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
    • Total assets (annual): USD 663.79MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
    2026-07-31INSIDERMunson Gillian transacted 685 sh — Director ~$7k
    2026-07-31INSIDERGoldstein Lainie transacted 377 sh — Director ~$4k
    2026-07-16INSIDERHui Yvonne sold 1.2k sh — Principal Accounting Officer ~$14k
    2026-07-15INSIDERLinetsky David transacted 69 sh — President, Network Solutions ~$1k
    2026-07-15INSIDERHui Yvonne transacted 937 sh — Principal Accounting Officer ~$10k
    2026-07-14INSIDEREgbuonu-Davis Lisa sold 536 sh — Director ~$6k
    2026-07-06INSIDERHui Yvonne sold 1.4k sh — Principal Accounting Officer ~$15k
    2026-06-30INSIDERHui Yvonne transacted 1.4k sh — Principal Accounting Officer ~$12k
    2026-06-30INSIDERHoffman Allison C transacted 1.3k sh — General Counsel & Secretary ~$11k
    2026-06-25 00:00 UTCINSIDER7 insider transactions — 2026-06 · net buy $1.1M
    2026-06-25INSIDEREgbuonu-Davis Lisa sold 2.5k sh — Director ~$24k
    2026-06-24INSIDEREgbuonu-Davis Lisa transacted 19.3k sh — Director ~$185k
    2026-06-24INSIDERKessler Jon transacted 19.3k sh — Director ~$185k
    2026-06-24INSIDERSayar Ramin transacted 19.3k sh — Director ~$185k
    2026-06-24INSIDERMunson Gillian transacted 19.3k sh — Director ~$185k
    2026-06-24INSIDERSmith Mark Douglas transacted 19.3k sh — Director ~$185k
    2026-06-24INSIDERGoldstein Lainie transacted 19.3k sh — Director ~$185k
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-05-28FILING10-Q filing →
    2026-05-27FILING8-K filing →
    2026-05-18 00:00 UTCINSIDER2 insider transactions — 2026-05
    2026-05-18INSIDERHui Yvonne transacted 325 sh — Principal Accounting Officer ~$3k
    2026-05-18INSIDERHui Yvonne sold 431 sh — Principal Accounting Officer ~$4k
    2026-05-14FILINGDEF 14A filing →
    2026-05-11FILING8-K filing →
    2026-05-04FILING8-K filing →
    2026-04-30 00:00 UTCINSIDER31 insider transactions — 2026-04 · net buy $895k
    2026-04-30INSIDERCAHILL EDWARD L transacted 1.1k sh — Director ~$10k
    2026-04-30INSIDERGoldstein Lainie transacted 1.1k sh — Director ~$10k
    2026-04-30INSIDERMunson Gillian transacted 1.1k sh — Director ~$10k
    2026-04-20INSIDERHoffman Allison C sold 6.2k sh — General Counsel & Secretary ~$56k
    2026-04-17INSIDERHui Yvonne sold 1.3k sh — Principal Accounting Officer ~$12k
    2026-04-16INSIDERLinetsky David transacted 229 sh — President, Network Solutions ~$2k
    2026-04-16INSIDERHui Yvonne sold 10.1k sh — Principal Accounting Officer ~$91k
    2026-04-07CONGRESSJosh Gottheimer (house) sale shares → $1,001 - $15,000
    2026-04-03FILING8-K filing →
    2026-03-31 00:00 UTCINSIDER1 insider transaction — 2026-03 · net buy $8.2M
    2026-03-31FILING10-K filing →
    Showing the 40 most recent of 58 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage